AlphaValue/ Baader downgrades Sandoz Group stock to Reduce

Published on 10/22/2026 at 09:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AlphaValue cut Sandoz to Reduce on October 19, 2026. Sandoz Group stock costs EUR 85.37 on October 22, 2026; biosimilars were 33 percent of first-half sales.

Business and valuation signals

AlphaValue/Baader Europe downgraded Sandoz to Reduce on October 19, 2026.
Biosimilars accounted for 33 percent of first-half sales in 2026.
Sandoz stock trades at EUR 85.37 at 9:18 a.m. CEST at Lang & Schwarz on October 22, 2026.
Sandoz is scheduled to publish its third-quarter sales update on October 27, 2026.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz stock (ISIN CH1243598427) was trading at EUR 85.37 at Lang & Schwarz on October 22, 2026, at 9:18 a.m. CEST. The latest analyst action came from AlphaValue/Baader Europe, which downgraded Sandoz to Reduce on October 19, 2026, as MarketScreener reported.

What changed in the rating?

The downgrade adds a valuation counterweight after a strong run in the Swiss-listed stock. MarketScreener's company page showed a 35.68 percent gain since the start of 2026 and a market capitalization of CHF 33.9 billion on October 22, 2026. The same page listed 16 analysts and an average target of USD 95.00, although those figures use a separate reporting currency and are not comparable with the euro quote.

The analyst move comes ahead of Sandoz's next sales update. For investors, the key tension is the contrast between a higher-value biosimilar mix and continued pricing pressure in parts of the generics business.

What supports the biosimilar case?

Sandoz reported first-half 2026 net sales growth of 5 percent, while biosimilar sales grew 20 percent and reached 33 percent of total sales. Core EBITDA increased 15 percent, and the core EBITDA margin expanded by 90 basis points to 20.90 percent, according to the Yahoo Finance transcript of the August 5, 2026 earnings call.

Management also said the biosimilar pipeline contained 36 assets in the first half of 2026. North American biosimilar sales grew 47 percent, while the company said it was confirming its full-year 2026 guidance. The reported mix matters because biosimilars carry higher margins than the generics portfolio, according to management's remarks in the same transcript.

When is the next update?

Sandoz is scheduled to publish its third-quarter sales and revenue release on October 27, 2026, according to MarketScreener. That update should provide the next quantified test of biosimilar growth, pricing pressure and the confirmed full-year outlook.

Stock price and investor context

Sandoz Group's primary listing is on the Swiss Exchange, where the stock was quoted at CHF 78.40 on October 22, 2026, according to the market data snapshot. The 52-week range was CHF 47.73 to CHF 78.84, placing the Swiss quote near the upper end of that interval.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.